Collegium director sells 20 shares at $34.05
Collegium Pharmaceutical director John Gordon Freund reported a small open-market sale of common stock.
Rhea-AI Filing Summary
Collegium Pharmaceutical director John Gordon Freund reported a small open-market sale of common stock. On May 18, 2026, he sold 20 shares of Collegium Pharmaceutical common stock at $34.05 per share in a direct transaction.
After this sale, he directly held 83,952 common shares. The filing also shows indirect interests in entities holding 8,625 shares through Skyline Venture Management V, LLC and 23,129 shares through John Freund Family Partnership IV, L.P., with beneficial ownership disclaimed except for his proportionate pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 20 shares
Net Sell
3 txns
Insider
Freund John Gordon
Role
Director
Sold
20 shs ($681.00)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 20 | $34.05 | $681.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 83,952 shares (Direct);
Common Stock — 23,129 shares (Indirect, By: John Freund Family Partnership IV, L.P.);
Common Stock — 8,625 shares (Indirect, By: Skyline Venture Management V, LLC)
Footnotes (2)
- F1. The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The Reporting Person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The Reporting Person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein.
- F2. The shares are held by Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management V, LLC. The Reporting Person disclaims beneficial ownership of all the shares held by Skyline Venture Management V, LLC except to the extent of his proportionate pecuniary interest therein.
Key Figures
Shares sold: 20 shares
Sale price: $34.05 per share
Direct holdings after sale: 83,952 shares
+2 more
5 metrics
Shares sold
20 shares
Open-market sale of common stock on May 18, 2026
Sale price
$34.05 per share
Price for 20 common shares sold
Direct holdings after sale
83,952 shares
Common stock directly held following the transaction
Indirect Skyline holdings
8,625 shares
Common stock held by Skyline Venture Management V, LLC
Indirect partnership holdings
23,129 shares
Common stock held by John Freund Family Partnership IV, L.P.
Key Terms
open-market sale, indirect ownership, beneficial ownership, pecuniary interest, +1 more
5 terms
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"ownership_type": "indirect" and nature_of_ownership by entities"
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of the shares held"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his proportionate pecuniary interest therein"
voting and investment power financial
"These individuals share voting and investment power over the shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did COLLEGIUM PHARMACEUTICAL (COLL) report for John Gordon Freund?
Collegium Pharmaceutical reported that director John Gordon Freund sold 20 shares of common stock in an open-market transaction at $34.05 per share, while maintaining substantial remaining holdings both directly and through affiliated investment entities.
What was the sale price in John Gordon Freund’s recent COLLEGIUM PHARMACEUTICAL stock transaction?
The 20 Collegium Pharmaceutical common shares sold by John Gordon Freund were transacted at $34.05 per share. This price applies only to the directly sold shares disclosed as an open-market or private transaction in the insider report.
How are John Gordon Freund’s indirect COLLEGIUM PHARMACEUTICAL holdings structured?
Indirect holdings are reported through Skyline Venture Management V, LLC and John Freund Family Partnership IV, L.P. He shares voting and investment power or participates via a revocable trust and disclaims beneficial ownership except for his proportionate pecuniary interest in those entities.
Does the COLLEGIUM PHARMACEUTICAL Form 4 show any option exercises or derivative transactions for John Gordon Freund?
The Form 4 lists no derivative securities or option exercises for John Gordon Freund. All reported positions are in Collegium Pharmaceutical common stock, comprising one small direct sale and updated direct and indirect share holdings as of the transaction date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
